KYORIN Holdings, Inc.
4569.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$60.61B
Close$
$-590.22
155.9% downside
Current Fair Value
155.9% downsideOvervalued by 155.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $60.61 Billion |
|---|---|
| Enterprise Value | $70.18 Billion |
| Dividend Yield | $57.00 (4.45%) |
| Earnings per Share | $60.02 |
| Beta | 0.16 |
| Outstanding Shares | 57,446,271 |
Return
| Return on Equity | 1.55% |
|---|---|
| Return on Assets | 1.15% |
| Return on Invested Capital | 1.32% |
Valuation & Multiples
| P/E Ratio | 27.91 |
|---|---|
| PEG | -45.93 |
| Price to Sales | 0.48 |
| Price to Book Ratio | 0.43 |
| Enterprise Value to Revenue | 0.56 |
| Enterprise Value to EBIT | 32.51 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$29.65 B
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$29.58 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About KYORIN Holdings, Inc.
1,982 employees
CEO: Yutaka Ogihara Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents....